Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis..
Diabetologia. 59(1), 30-43.
(2016). Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship?.
Curr Vasc Pharmacol.
(2023). The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature..
J Clin Gastroenterol. 45(1), 50-4.
(2011). Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis..
Expert Opin Investig Drugs. 24(2), 145-57.
(2015). The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease..
Curr Mol Med. 12(1), 68-82.
(2012). Activin A and follistatin in patients with nonalcoholic fatty liver disease..
Metabolism. 65(10), 1550-8.
(2016). Thyroid nodules - stepwise diagnosis and management..
Hormones (Athens). 6(2), 101-19.
(2007). Irisin: a renaissance in metabolism?.
Metabolism. 62(8), 1037-44.
(2013). The association between Helicobacter pylori infection and insulin resistance: a systematic review..
Helicobacter. 16(2), 79-88.
(2011). Nonalcoholic fatty liver disease and polycystic ovary syndrome..
Ann Hepatol. 14(6), 941-3.
(2015). An update on the validity of irisin assays and the link between irisin and hepatic metabolism..
Metabolism. 64(9), 937-42.
(2015). Sarcopenia: still in relative definition-penia and severe treatment-penia..
Metabolism. 155717.
(2023). Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis..
Ann Hepatol. 19(5), 579-580.
(2020). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid..
Support Care Cancer. 17(10), 1329-30.
(2009). Irisin in patients with nonalcoholic fatty liver disease..
Metabolism. 63(2), 207-17.
(2014). Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520-525..
Diabetes Care. 35(7), e53; author reply e54.
(2012). Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name..
Metabolism. 113, 154413.
(2020). Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need..
Curr Med Res Opin. 38(6), 885-888.
(2022). Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis..
Endocrine. 62(2), 487-489.
(2018). Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man..
Arq Bras Endocrinol Metabol. 54(6), 578-82.
(2010). Bone and fat interplay in inflammatory bowel disease: clinical implications and future perspectives..
Inflamm Bowel Dis. 20(11), E22.
(2014). Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology..
J Clin Gastroenterol.
(2019). Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease..
J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
(2011).